Frontiers in Gastroenterology · Nov 9, 2026
Metformin prevents and accelerates the resolution of spasmolytic polypeptide-expressing metaplasia in mice
By Shiyi Ge, Jia-Le Li, Xingxing Zhou et al.
Background Spasmolytic polypeptide-expressing metaplasia (SPEM) is a gastric precancerous lesion with no approved pharmacological therapy. Metformin has demonstrated chemoprophylactic activity against gastric cancer; however, its effect on SPEM is unknown. We investigated whether metformin could prevent or reverse SPEM and the underlying mechanisms. Methods C57BL/6 mice were treated with tamoxifen to induce SPEM. Metformin was administered prophylactically (7 days before tamoxifen) or therapeutically (3, 7, 10, or 14 days after tamoxifen). SPEM phenotypes were assessed by histology, immunohistochemistry and immunofluorescence. Transcriptomic sequencing was performed; differentially expressed genes were analyzed by GO, KEGG and GSEA enrichment. LCN2 expression was evaluated by multiplex immunofluorescence. Results Metformin significantly attenuated tamoxifen-induced gastric glandular atrophy, reduced SPEM cell numbers (TFF2⁺, AQP5⁺) and preserved parietal cells (ATP4α⁺) in both prophylactic and therapeutic regimens. Transcriptomic analysis identified 511 DEGs intersecting the tamoxifen-upregulated and day-3-metformin-downregulated gene sets. KEGG and GSEA analyses revealed that the NF-κB signaling pathway was significantly upregulated in SPEM, and downregulated by metformin. LCN2 was upregulated in SPEM and was lower after metformin. Moreover, CD163⁺ M2 macrophage infiltration was markedly increased in the SPEM mucosa and suppressed after metformin treatment. Conclusions Metformin prevented and accelerated the resolution of tamoxifen-induced SPEM in mice. These effects were associated with lower transcriptional enrichment of the NF-κB pathway, lower LCN2 expression, and fewer CD163⁺ M2 macrophages. These findings identify metformin as a potential pharmacological agent for gastric SPEM and highlight the role of LCN2-related inflammation in gastric precancerous progression.